Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Effervescent Tablet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Effervescent Tablet. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2010-023485-53 Sponsor Protocol Number: IJG-PAR-2010 Start Date*: 2011-04-20
    Sponsor Name:IDIAP JORDI GOL I GURINA
    Full Title: Evaluation of the relationship between effervescent acetaminophen and blood pressure. A clinical trial.
    Medical condition: Evaluation of whether paracetamol effervescent formulation increases blood pressure compared with effervescent paracetamol formulation does not
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002754-22 Sponsor Protocol Number: BUM-4/GVH Start Date*: 2006-03-14
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: An open, randomized, multicentre phase II pilot study to evaluate the efficacy of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD using different application durati...
    Medical condition: oral chronic graft versus host disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006117-16 Sponsor Protocol Number: Puranik 07-03/23 Start Date*: 2008-07-31
    Sponsor Name:Betsi Cadwaladr University Health Board
    Full Title: A prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (BuTrans 20µg/h) matrix transdermal patch in the management of post tonsillectomy ...
    Medical condition: post-tonsillectomy pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001484-12 Sponsor Protocol Number: BUL-1/EEA Start Date*: 2015-09-22
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathol...
    Medical condition: Active eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016692-29 Sponsor Protocol Number: BUU-2/EEA Start Date*: 2012-02-20
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspen...
    Medical condition: Active eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001485-99 Sponsor Protocol Number: BUL-2/EER Start Date*: 2015-12-08
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mai...
    Medical condition: Maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005040-35 Sponsor Protocol Number: 0120 Start Date*: 2021-01-28
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of effervescent and buffered alendronate on bone turnover compared to conventional alendronate: A randomized non-inferiority trial
    Medical condition: Osteopenia, i.e. bone mineral density T-score < -1
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10005991 Bone mass decreased LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003570-11 Sponsor Protocol Number: BC-6072 Start Date*: 2019-10-21
    Sponsor Name:Ghent University Hospital
    Full Title: The use of buffered soluble alendronate 70 mg (Steovess/Binosto) after denosumab discontinuation to prevent increase in bone turnover.
    Medical condition: erosive osteoarthritis of the interphalangeal finger joints
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10016686 Finger osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006837-28 Sponsor Protocol Number: PML_DOC_0804 Start Date*: 2008-12-08
    Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine
    Full Title: Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N-acetylcysteine on small airways and on inflammation and oxidative stress in COPD pat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003946-13 Sponsor Protocol Number: PML_NAC_01 Start Date*: 2007-09-05
    Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine
    Full Title: Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N acetylcysteine on small airways and on inflammation and oxidative stress in COPD pat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000060-20 Sponsor Protocol Number: 2018-08-EFT-1 Start Date*: 2019-12-20
    Sponsor Name:HEXAL AG
    Full Title: Efficacy and safety of acetylcysteine for the treatment of acute uncomplicated rhinosinusitis: a prospective, randomized, double-blind, placebo-controlled trial
    Medical condition: Acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004562-10 Sponsor Protocol Number: BUM-5/GVH Start Date*: 2009-07-29
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wi...
    Medical condition: Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed) FR (Completed) SE (Completed) IT (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004466-14 Sponsor Protocol Number: RH01361 Start Date*: 2011-10-27
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: Effects of two doses of a common cold treatment on cognitive function
    Medical condition: Common cold
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10000938 Acute nasopharyngitis (common cold) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002322-12 Sponsor Protocol Number: Ironsuppletiontrial Start Date*: 2014-07-24
    Sponsor Name:Rijnstate Hospital
    Full Title: Optimizing Iron suppletion trial after Roux- en -Y Gastric Bypass
    Medical condition: Patients who underwent a gastric bypass and develop an irondeficiency postoperatively. The medical condition which is investigated is irondeficiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002323-10 Sponsor Protocol Number: absorptiontrial Start Date*: 2014-07-21
    Sponsor Name:Rijnstate
    Full Title: Iron absorptiontrail after Roux- en -Y Gastric Bypass
    Medical condition: Patients who are eligible for a primary Roux- en -Y gastric bypass and who have no irondificiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012707-26 Sponsor Protocol Number: Acetilcisteina-Ocronosi-SI/2009 Start Date*: 2010-05-27
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: THERAPEUTIC EFFECTIIVENESS OF N-ACETYL-CYSTEINE AND ASCORBIC ACID IN PATIENTS WITH ALKAPTONURIA-OCHRONOSIS
    Medical condition: patient affected by alkaptonuria-ocronosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005015-17 Sponsor Protocol Number: GE09-01 Start Date*: 2009-05-13
    Sponsor Name:VU university medical centre
    Full Title: Effect of N-acetylcysteine on thiopurine related hepatotoxicity in IBD patients
    Medical condition: adult patients (18-70 years old) who have been treated with azathioprine, 6-mercaptopure or 6-thioguanine for inflammatory bowel disease, in whom hepatotoxicity occured as an adverse event, are eli...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005809-38 Sponsor Protocol Number: NACP1 Start Date*: 2006-12-08
    Sponsor Name:Research & Development Department, Addenbrookes Hospital
    Full Title: Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography
    Medical condition: We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients underg...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003651-12 Sponsor Protocol Number: NAC-E-23 Start Date*: 2005-11-11
    Sponsor Name:ZAMBON, S.A.
    Full Title: NAC EFFECT ON OXIDATIVE STRESS AND MUSCLE FUNCTION IN COPD PATIENTS. Efecto de NAC en estrés oxidativo y función muscular en pacientes con EPOC
    Medical condition: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001098-25 Sponsor Protocol Number: NAC-E-21 Start Date*: 2004-08-23
    Sponsor Name:Zambon SA
    Full Title: N-Acetylcisteine (NAC) effect on the inmunologycal system
    Medical condition: Postmenopausal health woman aged more than 50 years
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA